# Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab

> **NCT04407442** · PHASE2 · TERMINATED · sponsor: **University of California, San Francisco** · enrollment: 5 (actual)

## Conditions studied

- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **DRUG:** Azacitidine
- **BIOLOGICAL:** Daratumumab
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04407442
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-30
- **Primary completion:** 2023-04-30
- **Final completion:** 2023-04-30
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Slow enrollment and change in sponsor direction
- **Last updated:** 2024-04-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04407442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04407442, "Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04407442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*